Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Results of regression analyses for the comorbidities in the secondary analysis

From: Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L

    K-BILD
  EQ-5D EBVS VAS Total Breathlessness Chest symptoms Psychological impact
Est. Est. Est. Est. Est. Est.
Comorbidities
 Pulmonary hypertension −0.02 2.99 2.43 1.74 5.71 3.33
 Arterial hypertension −0.05* −2.96 −2.75 −6.85* −1.04 − 2.08
 Coronary heart disease −0.02 −4.70 −2.06 − 2.90 −5.97 − 2.51
 Congestive heart failure 0.05 −4.57 2.12 3.22 3.81 1.81
 Other CVD 0.02 10.96 4.07 0.98 16.60 5.34
 Diabetes mellitus −0.03 −0.96 −1.89 0.35 −3.94 −1.91
 Emphysema/COPD −0.06 − 3.02 − 3.18 −6.03 −9.11 −2.38
 Lung cancer 0 0 0 0 0 0
 Depression −0.08 −5.27 −5.36 −5.69 −17.04** −5.87
 GERD 0.04 −6.87 −0.86 −1.72 −4.39 −2.62
 Renal failure 0.08 2.83 3.79 8.87 6.28 1.82
 OSAS −0.05 −6.11 −1.71 −3.66 −8.22 −1.44
 Thromboembolism −0.11 −2.82 −2.27 0.31 −9.70 −4.93
 Malignant tumor −0.01 −13.66 −0.68 3.60 −13.06 −1.28
  1. Values depicted are the beta estimates of regression coefficients,all adjusted for age, sex, education, employment,clinic location, smoking status, FVC % pred, DLCO % pred, disease suptype. Abbreviations Est-estimates, IPF idiopathic pulmonary fibrosis, HP: hypersensitivity pnemonitis 1including: non-specific interstitial pneumonia, desquamative interstitial pneumonia, cryptogenetic organizing pneumonia, lymphocytic interstitial pneumonia,respiratory bronchiolitis associated interstitial lung disease, pleuropulmonary fibroelastosis, and acute interstitial pneumonia. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001